B Cell Design innovates in response to the shortage of diagnostic reagents

The Aton Group, through its subsidiary B Cell Design, is positioning itself in the rapidly evolving in vitro diagnostics (IVD) sector. Faced with the challenges of strict regulations and the scarcity of Disease State Plasma (DSP), B Cell Design is offering a promising alternative. The company is developing monoclonal antibodies to human Fc derived from transgenic mice. This patented innovation aims to replace blood plasma from diseased donors.

The antibodies produced by B Cell Design offer industrial reproducibility, ensuring consistent quality that is difficult to achieve with human plasma. Furthermore, they are designed to meet European IVD standards, thus simplifying compliance efforts for manufacturers. Patents filed on mouse cell lines provide a distinct competitive advantage.

Commercial development is underway, and discussions with several manufacturers in the IVD sector are promising. This strategic initiative reflects the Aton Group's commitment to positioning technological assets that address critical needs in the healthcare sector.